{
  "ticker": "LLY",
  "target_date": "2025-04-23",
  "actual_date": "2025-04-23",
  "collected_at": "2025-12-08T11:40:41.944219",
  "price": {
    "open": 832.2,
    "high": 841.19,
    "low": 813.98,
    "close": 824.6981811523438,
    "volume": 2714600,
    "change_1d_pct": 0.23,
    "change_7d_pct": 13.25,
    "change_30d_pct": 0.65
  },
  "technicals": {
    "rsi_14": 51.58,
    "sma_20": 778.84,
    "sma_50": 827.98,
    "macd": -5.42,
    "macd_signal": -16.966,
    "macd_histogram": 11.546,
    "bb_upper": 866.6,
    "bb_lower": 691.08,
    "price_vs_sma20_pct": 5.89,
    "price_vs_sma50_pct": -0.4,
    "volume_ratio": 0.69
  },
  "fundamentals": {
    "market_cap": 889410617344,
    "pe_ratio": 48.610485,
    "forward_pe": 43.78376,
    "price_to_book": 37.35467,
    "price_to_sales": 14.968253,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.78,
    "pct_from_52w_low": 59.05
  },
  "macro": {
    "spy": {
      "price": 532.37,
      "change_1d_pct": 1.55,
      "change_7d_pct": -0.69
    },
    "vix": {
      "level": 28.45,
      "signal": "HIGH_FEAR"
    },
    "treasury_10y": {
      "yield_pct": 4.39
    },
    "dollar_index": {
      "level": 99.84
    },
    "gold": {
      "price": 3276.3
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Eli Lilly sues Mochi Health and others for \u2018deceptive\u2019 tirzepatide marketing",
      "source": "Yahoo",
      "datetime": 1745431302,
      "summary": "The lawsuit filings are the latest turn in a long-running legal saga between GLP-1RAs makers and compounders.",
      "url": "https://finnhub.io/api/news?id=7fe7ec424e0631289a4f9fbffb6ee9109932692a44ab8046216b5d4923f3e5cc"
    },
    {
      "headline": "Eli Lilly is stepping up its fight against copycat weight loss drugs",
      "source": "Yahoo",
      "datetime": 1745424840,
      "summary": "In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth companies that offer cheaper versions of its blockbuster GLP-1 weight loss drugs Mounjaro and Zepbound.",
      "url": "https://finnhub.io/api/news?id=f126f4a82d1dbadaad43371a861e776a56878b017ec669cea5d8fac8706cd1e9"
    },
    {
      "headline": "Top Midday Stories: Boeing to Ask FAA to Lift Production Cap; Musk Says His Government Commitment to 'Drop Significantly'",
      "source": "Yahoo",
      "datetime": 1745424164,
      "summary": "All three major US stock indexes were up sharply, with the Nasdaq Composite gaining nearly 3% in lat",
      "url": "https://finnhub.io/api/news?id=0d0a3314a49af396408734d9c53dde14f07e670204d7aec83fbdb856c046d400"
    },
    {
      "headline": "Is Eli Lilly and Company (LLY) the Best Stock That Will Always Grow?",
      "source": "Yahoo",
      "datetime": 1745417933,
      "summary": "We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best stocks that will always grow. The Looming Risk of a Recession in the US Threats of an impending recession are looming",
      "url": "https://finnhub.io/api/news?id=41d150d8467940c01796d659fce93aff5c1b99a817c900a5a58660838490cd85"
    },
    {
      "headline": "Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug",
      "source": "Yahoo",
      "datetime": 1745416380,
      "summary": "Eli Lilly (NYSE: LLY) has been growing its sales at a good clip over the past year.  This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in quarterly sales, although it was approved only in late 2023.  Zepbound's prospects still look bright, but s",
      "url": "https://finnhub.io/api/news?id=734c87b8fa30b8adf3c44a145a15c9fab121139d3006e1e8501f84e3a64831fc"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-04-22",
      "description": "xslF345X05/wk-form4_1745353361.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000124/xslF345X05/wk-form4_1745353361.xml"
    },
    {
      "form": "4",
      "date": "2025-04-22",
      "description": "xslF345X05/wk-form4_1745353273.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000122/xslF345X05/wk-form4_1745353273.xml"
    },
    {
      "form": "4",
      "date": "2025-04-22",
      "description": "xslF345X05/wk-form4_1745353160.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000120/xslF345X05/wk-form4_1745353160.xml"
    },
    {
      "form": "4",
      "date": "2025-04-22",
      "description": "xslF345X05/wk-form4_1745352964.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000118/xslF345X05/wk-form4_1745352964.xml"
    },
    {
      "form": "4",
      "date": "2025-04-22",
      "description": "xslF345X05/wk-form4_1745352850.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000116/xslF345X05/wk-form4_1745352850.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}